Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC reduced its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 80.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,157 shares of the company's stock after selling 182,068 shares during the quarter. Sherbrooke Park Advisers LLC owned 0.08% of Fulcrum Therapeutics worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth $38,000. Mariner LLC acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at about $78,000. Cantor Fitzgerald L. P. purchased a new position in Fulcrum Therapeutics during the 4th quarter valued at about $94,000. Zacks Investment Management acquired a new position in Fulcrum Therapeutics during the fourth quarter worth about $99,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after purchasing an additional 13,057 shares in the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on FULC. HC Wainwright reissued a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. Leerink Partners upgraded Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the company from $4.00 to $12.00 in a report on Friday. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday. Finally, Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price target for the company in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $5.83.

Fulcrum Therapeutics Stock Up 5.2%

Shares of FULC traded up $0.32 on Monday, hitting $6.44. 898,658 shares of the stock traded hands, compared to its average volume of 972,394. Fulcrum Therapeutics, Inc. has a 1 year low of $2.32 and a 1 year high of $10.13. The stock's 50 day moving average is $4.03 and its two-hundred day moving average is $3.91. The firm has a market capitalization of $347.62 million, a P/E ratio of -20.77 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. Research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.